Skip to main content
. 2017 Aug 25;7:9473. doi: 10.1038/s41598-017-09958-9

Figure 4.

Figure 4

Neonatal UCBT prevents GAGs accumulation in MPS-I mice. (A) Donor chimerism (percentage of CD45.1+ cells) determined by flow cytometry in the PB of recipient MPS-I and WT mice at 20 weeks (time of sacrifice) after nUCBT (n = 12 for MPS-I, n = 12 for WT; p = 0.24 by Wilcoxon test). Dashed line indicates the level of 50% donor engraftment, and identifies the highly-engrafted mice group (with ≥50% donor cells in PB, nUCBT-hi). (B) IDUA activity in spleen, liver, lung, kidney, and heart of WT (n = 8), MPS-I (n = 8), MPS-I nUCBT-hi (n = 5), and MPS-I nUCBT-lo mice (n = 5). (C) GAG levels in the indicated organs of the same WT, MPS-I, MPS-I nUCBT-hi, and MPS-I nUCBT-lo mice. (D) Levels of ΔDiHS-0S, ΔDiHS-NS, ΔDi-4S, and mono-sulfated KS in the plasma of the mice. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 by Wilcoxon test.